{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"180","value":"146"}]}],"title":"Peritumor area gadolinium rCBV"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"180","value":"136"}]}],"title":"Peritumor area ferumoxytol rCBV"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"180","value":"39"}]}],"title":"Tumor area gadolinium rCBV"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"180","value":"54"}]}],"title":"Tumor area ferumoxytol rCBV"}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"Compare rCBV measurements in regions of interest obtained from ferumoxytol DSC-MRI with gadolinium based contrast agent (GBCA) MR images to evaluate vascular properties of brain tumors. CBV maps were generated by applying tracer kinetic model to the first pass of the contrast bolus. Voxelwise CBV maps were coregistered to T1 weighted images and then normalized by dividing by the mean of normal appearing white matter CBV in the same region in the contralateral hemisphere. RCBV values (as the area under the signal intensity curve, normalized by the area under the curve for the control region) were obtained. Values range from 0 (low intensity) to 180 (highest intensity).","dispersionType":"Full Range","groups":[{"description":"Study patients: adult patients with high grade primary malignant brain tumors or with known or suspected brain metastases from histologically confirmed primary cancer\n\nStudy procedures: patients will receive IV ferumoxytol (maximum dose 4 mg/kg, over at least 15 minutes) beginning approximately 15 seconds after start of 3T DSC-MRI and GBCA IV approximately 1 minute and 50 seconds after start of 3T DCE-MRI on day 1. Patients will also undergo MRI without contrast at baseline (before and on day 2. Imaging with ferumoxytol, GBCA and without contrast repeats every 3 weeks for a total of 6 more imaging sessions over up to 5 years.\n\n3 Tesla Magnetic Resonance Imaging: Undergo 3T MRI\n\nDynamic Contrast-Enhanced Magnetic Resonance Imaging: Undergo 3T DCE-MRI\n\nDynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging: Undergo 3T DSC-MRI\n\nFerumoxytol: Given IV\n\nGadolinium: Given IV\n\nMRI-Based Angiogram: Undergo MRA","id":"OG000","title":"Malignant Brain Tumor Patients Undergoing Brain MRI"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"Summarized after completion of up to 6 imaging sessions (up to 5 years)","title":"Utility of Ferumoxytol and Gadolinium Based Contrast Agents for Improved Imaging Biomarkers of Malignant Brain Tumors in a Single Imaging Session by Comparing Dynamic Susceptibility Contrast (DSC) Determined Relative Cerebral Blood Volume (rCBV) Maps.","type":"PRIMARY","unitOfMeasure":"Values on a scale"}